Inflammatory Bowel Disease Mechanisms and Therapeutic Strategies

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, arises from a complex interplay of genetic predisposition, environmental triggers and immune dysregulation. A primary defect in epithelial barrier integrity permits translocation of luminal microbes, leading to dysbiosis and exaggerated activation of innate immune sensors. Key signalling pathways, notably NF-κB and the NLRP3 inflammasome, drive the release of pro-inflammatory cytokines such as tumour necrosis factor-α and interleukin-1β, while defects in autophagy and regulatory T-cell function impair resolution of inflammation. Oxidative stress and secondary carbonyl lesions further exacerbate mucosal injury, reinforcing a vicious cycle of tissue damage. Therapeutic strategies have historically targeted broad immunosuppression with aminosalicylates, corticosteroids and thiopurines, and more recently have incorporated biologics directed against TNF-α, integrins or interleukins. Small-molecule inhibitors of Janus kinases and sphingosine-1-phosphate receptors offer oral alternatives by blocking intracellular signalling or lymphocyte trafficking. Modulation of the gut microbiome through faecal microbiota transplantation, probiotics or dietary interventions seeks to restore microbial balance, while emerging cell-based approaches harness regulatory dendritic cells or mesenchymal stem cells. Precision medicine, guided by genetic risk loci and microbial profiling, aims to match patients with the most effective and least toxic therapies, thereby reducing long-term complications and improving quality of life worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Inflammatory Bowel Disease Mechanisms and Therapeutic Strategies publication trend

The graph below shows the total number of articles in inflammatory bowel disease mechanisms and therapeutic strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Dysbiosis: An imbalance in the composition or function of the gut microbiota that can drive mucosal inflammation.

NF-κB (Nuclear Factor κB): A transcription factor central to the regulation of genes involved in immune and inflammatory responses.

NLRP3 Inflammasome: A cytosolic multi-protein complex that activates caspase-1 to mediate the maturation and release of interleukin-1β and interleukin-18.

Autophagy: A cellular process for degrading and recycling intracellular components, which contributes to immune homeostasis and clearance of pathogens.

Myeloperoxidase: An enzyme produced by neutrophils that generates reactive oxygen species and serves as a marker of neutrophil-driven inflammation.

References

1. A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans. Frontiers in Immunology (2023).
2. Aspergillus awamori: potential antioxidant, anti-inflammatory, and anti-apoptotic activities in acetic acid-induced ulcerative colitis in rats. Inflammopharmacology (2024).
3. A Novel Combination Therapy Using Rosuvastatin and Lactobacillus Combats Dextran Sodium Sulfate-Induced Colitis in High-Fat Diet-Fed Rats by Targeting the TXNIP/NLRP3 Interaction and Influencing Gut Microbiome Composition. Pharmaceuticals (2021).
4. Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies. Journal of Inflammation (2020).
5. Classical and recent advances in the treatment of inflammatory bowel diseases. Brazilian Journal of Medical and Biological Research (2015).
6. Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer. Oxidative Medicine and Cellular Longevity (2015).